Core Insights - The article highlights the successful collaboration between the Haimen High-tech Zone and the Changjiang Drug Research Institute, which has accelerated the development and commercialization of pharmaceutical products, exemplified by the rapid development of fish bladder-derived active peptide products [1][2]. Group 1: Collaborative Innovation - The partnership between the Haimen High-tech Zone and the Changjiang Drug Research Institute has led to a significant reduction in the development timeline for pharmaceutical products, achieving results in just six months instead of the usual three to five years [1]. - The collaboration has resulted in the establishment of a dual demand and problem-solving list, facilitating targeted research and development efforts that have saved companies over 5 million yuan in costs [2]. Group 2: Talent Development - The Changjiang Drug Research Institute has partnered with nearly 20 universities and research institutions to create a joint graduate training base, fostering a seamless connection between classroom learning, laboratory work, and production [3]. - Over the past six years, this initiative has produced more than 300 professional master's graduates and 200 high-end industry workers, with 80% choosing to start their careers within the Haimen High-tech Zone [3]. Group 3: Future Prospects - Looking ahead, the Changjiang Drug Research Institute plans to focus on cutting-edge fields such as anti-tumor drugs and medical devices during the 14th Five-Year Plan period, while the Haimen High-tech Zone aims to enhance its pilot platform and optimize talent policies [3]. - The goal is to create a comprehensive innovation ecosystem that integrates basic research, technical problem-solving, result transformation, and industrial application, ultimately establishing Haimen as a national hub for industry-academia-research collaboration [3].

每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 曾健辉） 每经AI快讯，采纳股份（SZ 301122，收盘价：25.3元）10月9日晚间发布公告称，采纳科技股份有限公 司全资子公司江苏采纳医疗科技有限公司，于近日收到国家知识产权局颁发的专利证书。专利名称 为"一次性使用人体动脉血样采集器"。 2024年1至12月份，采纳股份的营业收入构成为：医用产品占比51.23%，兽用产品占比39.03%，实验室 耗材占比7.61%，其他占比2.13%。 截至发稿，采纳股份市值为31亿元。 ...